Pioneering diagnostics
E.g., 20/06/2018
E.g., 20/06/2018

2004 Sales up 5.2% at Constant Exchange Rates

19 January, 2005

Marcy l'Etoile, France - January 19, 2005. bioMérieux, a global leader in the field of in vitro diagnostics, today announced its 2004 sales.

bioMérieux launches VITEK® 2 Compact to complete its VITEK 2 range

06 January, 2005

Marcy l’Etoile, France - January 6, 2005. A world leader in the field of in vitro diagnostics, bioMérieux SA (Euronext: FR0010096479 – BIM) completes its VITEK® 2 range of automated microbial identification and susceptibility testing systems through the launch of VITEK...

bioMérieux acquires an option to license Applied NeuroSolutions’ Technology to diagnose Alzheimer’s disease

15 December, 2004

Marcy L’Etoile, France - December 15th, 2004. bioMérieux SA (Euronext: FR0010096479 – BIM) , announces today that it signed a non-exclusive agreement with Applied Neurosolutions granting bioMérieux SA an option to assess Applied Neurosolutions’ technology for the diagnosis of...

bioMérieux reveals VIDIA, its new automated immunoanalyser, in Paris at the Journées Internationales de Biologie

05 November, 2004

Marcy l'Etoile, France - November 5th, 2004. A major player in the in vitro diagnostics marketplace, bioMérieux announces the first official presentation of its new fully automated immunoanalyser, VIDIA®. The system will be presented to healthcare professionals at the Journées...

bioMérieux to assess potential of PlasmAcute® Technology for tuberculosis testing

25 October, 2004

Bergen, Norway - October 25, 2004. Novel Diagnostics ASA and bioMérieux announced today that they have signed an agreement that gives bioMérieux access to patented PlasmAcute® acute phase antibody detection technology for use in the field of tuberculosis detection.

Tuberculosis is a...

Nine-Month Sales Up 5.6% at Constant Exchange Rates

20 October, 2004

Marcy l'Etoile, France - October 20th, 2004. bioMérieux, a global leader in the field of in vitro diagnostics, today announced its sales for the first nine months of 2004.

bioMérieux signs New Agreements with Gen-Probe

07 October, 2004

Marcy l'Etoile, France - October 7th, 2004. bioMérieux receives a $ 1 million license fee for access to its markers for blood clotting disorders. bioMérieux to give Gen-Probe an option for the access to bioMérieux NUCLISENS EASYQ® platform. bioMérieux Gains Access to ribosomal RNA...

Appointment of an Independent Board Member - Composition of Audit and Compensation Committees

01 October, 2004

Marcy l'Etoile, France - October 1st, 2004.

  • bioMérieux announces the nomination of a new independent Board Member, Mr Michel Angé, Vice-Président of APICIL-Prévoyance, to its Board of Directors. This nomination brings the total number of company...

bioMérieux Announces 23% Increase in First-Half 2004 Operating Income and Net Income

01 October, 2004

Marcy l'Etoile, France - October 1st, 2004. bioMérieux, a global leader in the field of in vitro diagnostics, today announces a significant increase in its financial results for the six months ended June 30, 2004.

bioMérieux innovates further in the fight against AIDS

27 September, 2004

Marcy l'Etoile, France - September 27th, 2004. A major player in the field of in vitro diagnostics, bioMérieux confirms its constant commitment to the fight against AIDS with the launch of two new advanced 4th generation tests for HIV screening. VIDAS® HIV DUO ULTRA and VIDAS...